Top 10 Forestry Stocks To Watch For 2016: Sanofi(SNY)
sanofi-aventis engages in the discovery, development, and distribution of therapeutic solutions to improve the lives of everyone. The company offers a range of healthcare assets, including a broad-based product portfolio in prescription drugs, OTC/OTX, generics, vaccines, and animal health. It has a strategic alliance with Regulus Therapeutics Inc. to discover, develop, and commercialize micro-RNA therapeutics, initially in fibrosis. The company was founded in 1970 and is headquartered in Paris, France.
Advisors' Opinion:- [By Keith Speights]
Sanofi (NYSE: SNY ) and Regeneron Pharmaceuticals (NASDAQ: REGN ) have developed a new drug that could lower LDL even more effectively than popular statin drugs. In November, the two companies announced enrollment in a large late-stage clinical trial to study the effects of an antibody that could lower LDL levels by inhibiting an enzyme called PCSK9 that is involved in the production of cholesterol.
- [By Rich Duprey]
After watching sales of its macular degeneration drug Eyleatake off toward blockbuster status, biopharmaceuticals specialist Regeneron Pharmaceuticals (NASDAQ: REGN ) is eying new opportunities and bought the full rights to two novel ophthalmology programs it's been developing with Sanofi (NYSE: SNY ) .
- [By Jeff Reeves]
So how can you play this trend? The iShares MSCI France ETF (EWQ) is one way, via a diversified fund that owns some of the biggest names in France. Theres also oil giant Total (TOT), which is headquartered in France but has a global flavor, as well as French healthcare giant Sanofi (SNY)
- [By Keith Speights]
Eylea isn't the only feather in Regeneron's cap, though. The company partnered with Sanofi (NYSE: SNY ) on colorectal cancer drug Zaltrap, which gained FDA approval last August. While sales were slug! gish initially, a steep price cut for the drug to make it more competitive should help.
source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/top-10-forestry-stocks-to-watch-for-2016.html
No comments:
Post a Comment